Coronary Atherosclerosis Clinical Trial
Official title:
Atorvastatin Plus Fenofibric Acid in the Reduction of Intermediate
This study will examine how an approved drug (TriLipix), when used in combination with a statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque. Patients will be randomly assigned to receive either the study treatment (TriLipix plus Atorvastatin) or the comparison treatment (a placebo). Comparison of the effect on the makeup of plaque will be done by using coronary artery computed tomography angiography (CTA), which all participants will have at enrollment and at the end of the study (18 months after enrollment).
This study will examine how an approved drug (TriLipix), when used in combination with a
statin (a drug that lowers blood cholesterol levels), affects the makeup of plaque.
Comparison of the effect on the makeup of plaque will be done by using coronary artery CTA,
which all participants will have at enrollment and at the end of the study.
Those who meet the eligibility criteria and sign the informed consent will be enrolled on
study. Patients will be instructed on nutritional guidelines and other lifestyle changes for
heart-healthy living.
If a patient has had a coronary CTA within the past two (2) months, they will not undergo
the procedure at enrollment. If the patient has not had a coronary CTA within the past two
(2) months, they will undergo a coronary CTA with contrast. Patients will be randomly
assigned to receive either the study treatment (135 mg of TriLipix plus 40 mg of
Atorvastatin) or the comparison treatment (a placebo or two pills that contains no active
treatment). They will have a 50% chance of receiving the study treatment and a 50% chance of
receiving the comparison treatment. This is a double-blind study, which means the patient,
the research staff, and the physician will not know which treatment the patient is
receiving. However, in case of an emergency, this information is immediately available to
the physician.
Follow-up visits will occur at 3, 6, 12, and 18 months. All patients will have a CTA at the
end of treatment.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02265146 -
ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study
|
||
| Completed |
NCT02335086 -
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease
|
N/A | |
| Completed |
NCT00811772 -
Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis
|
N/A | |
| Recruiting |
NCT03322332 -
Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries
|
N/A | |
| Completed |
NCT02305953 -
Cytokines and Vascular Inflammation in Psoriasis
|
N/A | |
| Completed |
NCT01642173 -
Assessment of Coronary Plaque Composition Using Optical Coherence Tomography
|
Phase 1 | |
| Completed |
NCT02316782 -
Bifurcation Lesion Analysis and STenting / BLAST
|
||
| Completed |
NCT00548613 -
Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium
|
Phase 1 | |
| Terminated |
NCT00243308 -
Serp-1 for the Treatment of Acute Coronary Syndrome
|
Phase 2 | |
| Recruiting |
NCT05105750 -
A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
|
Phase 4 | |
| Completed |
NCT01722214 -
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
|
Phase 4 | |
| Suspended |
NCT00790764 -
Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)
|
Phase 2 | |
| Active, not recruiting |
NCT01061398 -
CT-FIRST: Cardiac Computed Tomography Versus Stress Imaging For Initial Risk STratification
|
N/A | |
| Completed |
NCT00431977 -
Validation Study of Coronary CT Angiography as a Screening Tool in Asymptomatic Diabetes
|
N/A | |
| Completed |
NCT00431717 -
Coronary Computed Tomography Angiography and SPECT in Asymptomatic Diabetes
|
N/A | |
| Recruiting |
NCT00155350 -
Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients
|
Phase 4 | |
| Recruiting |
NCT05708547 -
Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
|
||
| Terminated |
NCT02440646 -
Natural History of Coronary Atherosclerosis in Real-World Stable Chest Pain Patients Underwent Computed Tomography Angiography in Comparison With Invasive Multimodality Imaging
|
||
| Completed |
NCT02576704 -
Prognostic Value of Myocardial Perfusion Heterogeneity in Normal SPECT Studies
|
N/A | |
| Terminated |
NCT01268319 -
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
|
N/A |